Omada Health prices IPO at $19 per share, in middle of expected range

Omada Health priced its IPO at $19 per share, the midpoint of its $18-$20 range, raising $150 million through the sale of 7.9 million shares and valuing the virtual chronic care company at approximately $1.1 billion, consistent with its 2022 private valuation. The IPO, marking the second digital health debut in recent weeks, follows a 57% revenue increase in Q1 to $55 million and a narrowed net loss of $9.4 million, signaling renewed activity in the tech IPO market.

Analysis

Omada Health has successfully priced its Initial Public Offering at $19 per share, situating it at the midpoint of its $18 to $20 expected range. The offering comprises 7.9 million shares, generating $150 million in proceeds and valuing the virtual chronic care provider at approximately $1.1 billion. This valuation is notably consistent with its private market valuation achieved in 2022 following a $192 million funding round. Key institutional backers include U.S. Venture Partners, Andreessen Horowitz, and Fidelity's FMR LLC, each holding between 9% and 10% of the stock. Omada's financial performance demonstrates strong momentum, with first-quarter revenue increasing 57% year-over-year to $55 million, up from $35.1 million. For the full year 2024, revenue grew 38% to $169.8 million. Concurrently, the company has shown progress towards profitability, with its first-quarter net loss narrowing to $9.4 million from $19 million in the prior year. This IPO marks the second digital health offering in recent weeks, following Hinge Health, and contributes to a broader, moderately positive sentiment surrounding a reviving tech IPO market, which has also seen debuts from Circle Internet and eToro, with Chime Financial anticipated shortly.

Key Decisions for Investors

• Investors should note Omada Health's significant Q1 revenue growth of 57% and narrowed net losses, which, combined with an IPO valuation consistent with its 2022 private valuation, may present a compelling investment case in the resurgent digital health sector.
• Consider the company's position within the virtual chronic care market and monitor its ability to sustain revenue growth and continue its trajectory towards profitability post-IPO, especially in light of its performance relative to peers like Hinge Health.
• Factor in the broader positive momentum in the tech IPO market as a potential tailwind, but maintain a focus on Omada's specific execution capabilities and market penetration for long-term value creation.